3 results
Approved WMOCompleted
Primary: progression-free survival in the GSK1120212-group in comparison with the docetaxel group. Secondary: safety and tolerability, response rate, duration of response, overall survival, PK.
Approved WMOCompleted
Primary: To determine whether treatment with BKM120 plus fulvestrant prolongs PFS based on local investigator assessment compared to treatment with placebo plus fulvestrant for all patients regardless of PI3K pathway activation status (unkown status…
Approved WMOPending
The primary endpoint (equal or improved MSQoL-54 and Eq5d) at which the value of telemonitoring is determined is t = 2 years.Mapping the effects of digital consultations or hospital visits, for MS patients, informal carers and the Isala…